As an investor I would be at least as interested in how clinically meaningful the drug is.
Given the standard deviations of the clinical outcome data, the open label nature of the study and apparent propensity to be less than diligent with data and its presentation, I have decided against investing in $SAVA.
Certainly played right $SAVA has offered some amazing trading opportunities and still may.
Market Data 
Markets 
AI
